Marit Sjo Lorentzen
Operationeel Directeur bij ARCTICZYMES TECHNOLOGIES ASA
Vermogen: 49 562 $ op 31-05-2024
Actieve functies van Marit Sjo Lorentzen
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Operationeel Directeur | - | - |
| Directeur/Bestuurslid | - | - | |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Directeur/Bestuurslid | - | - |
Loopbaan van Marit Sjo Lorentzen
Opleiding van Marit Sjo Lorentzen
| University of Tromso | Undergraduate Degree |
Statistieken
Internationaal
| Noorwegen | 4 |
Operationeel
| Director/Board Member | 2 |
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
- Beurs
- Insiders
- Marit Sjo Lorentzen
- Ervaring
